The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index; 24 of the 50 sources its claims cite were checked for support.
The potential of respiration inhibition as a new approach to combat human fungal pathogens
Open accessAbstract
The respiratory chain has been proposed as an attractive target for the development of new therapies to tackle human fungal pathogens. This arises from the presence of fungal-specific electron transport chain components and links between respiration and the control of virulence traits in several pathogenic species. However, as the physiological roles of mitochondria remain largely undetermined with respect to pathogenesis, its value as a potential new drug target remains to be determined. The use of respiration inhibitors as fungicides is well developed but has been hampered by the emergence of rapid resistance to current inhibitors. In addition, recent data suggest that adaptation of the human fungal pathogen, Candida albicans, to respiration inhibitors can enhance virulence traits such as yeast-to-hypha transition and cell wall organisation. We conclude that although respiration holds promise as a target for the development of new therapies to treat human fungal infections, we require a more detailed understanding of the role that mitochondria play in stress adaption and virulence.
Overview
CoChat Summary
TL;DR
This review argues that the fungal respiratory chain is a promising but unproven target for new antifungals, because fungal-specific electron transport chain components exist and respiration is linked to virulence traits. However, resistance, host toxicity concerns, and evidence that respiration-inhibitor adaptation can enhance Candida albicans virulence mean more detailed understanding of mitochondrial stress adaptation is needed.
Key findings
- Invasive candidaemia carries mortality up to 40%, and resistance to current antifungals plus inherently resistant species such as Candida glabrata and Candida auris drive the need for new targets.
- Most fungal pathogens have classical respiratory Complexes I–IV plus a cyanide-insensitive alternative oxidase (AOX); C. glabrata lacks multi-subunit Complex I and AOX, and a third “parallel” ETC pathway in C. parapsilosis and C. albicans represents approximately 10% of total respiration capacity.
- Respiration inhibition can be fungistatic/fungicidal and synergistic with existing antifungals: a screen of a 300,000-compound library identified a fungal-specific Complex III inhibitor that was synergistic with fluconazole, and Complex III/AOX inhibition enhanced caspofungin susceptibility in C. parapsilosis.
- In the authors’ recent study, C. albicans pretreated with sodium nitroprusside (NO donor) plus salicylhydroxamic acid (SHAM) showed faster hyphal switching when inhibition was relieved and increased virulence in a mouse systemic candidiasis model, with higher kidney fungal burden and increased immune infiltrate; an aoxΔ mutant did not show the increased hyphal switching.
Methods
- Narrative review synthesizing published literature on fungal respiration, electron transport chain complexes I–IV, alternative oxidase, respiration inhibitors, and combinations with current antifungals.
- The paper discusses mechanistic and preclinical studies across fungal pathogens including C. albicans, C. glabrata, Aspergillus fumigatus, Cryptococcus neoformans, Candida parapsilosis, and Pneumocystis jirovecii.
- It also cites the authors’ recent experimental study using C. albicans treated with SNP and SHAM, including a mouse model of systemic candidiasis; no new primary data are reported in this review.
Limitations
- The paper states that the physiological roles of mitochondria in pathogenesis remain largely undetermined, that the value of respiration as a drug target remains to be determined, and that a more detailed understanding of mitochondrial roles in stress adaptation and virulence is required.
- It states that conservation of respiratory machinery in eukaryotes raises toxicity concerns, that rapid resistance to current respiration inhibitors is a problem, and that development of fungal AOX inhibitors is hampered by lack of suitable fungal and highly specific inhibitors and by only Trypanosoma brucei AOX structure being available.
- Evident from the text: this is a narrative review without a stated systematic search or meta-analysis, so its conclusions depend on selected cited studies and on the authors’ prior experimental work rather than on newly generated or systematically appraised evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
23 Valid · 3 Not valid · 19 Not checked · 16 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Along with Complex I, Complex III is a major source of mitochondrial ROS accumulation (Meunier et al. 2013).”
§ The potential of respiration inhibition as a new approach to combat human fungal pathogens > Inhibition of respiration in human fungal pathogens > Complex III inhibition
What the sources say
- Supportedcites Meunier et al. 2013 source
Section 1.3 states directly that, along with Complex I, Complex III is a main site of ROS production. This supports the citing sentence’s description of Complex III as a major mitochondrial ROS source. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“reports suggest that AOX is dispensable for virulence in some fungal pathogens, including C. albicans (Huh and Kang 2001) and A. fumigatus (Grahl et al. 2012).”
§ The potential of respiration inhibition as a new approach to combat human fungal pathogens > Targeting alternative oxidase function
What the sources say
- Not checked — no full text of the sourcecites Huh and Kang 2001 source
- Supportedcites Grahl et al. 2012 source
The Grahl et al. citation supports the A. fumigatus part of the sentence; C. albicans has a separate citation. In the Results section, the ΔaoxA mutant showed no difference in virulence from wild type in a murine model, and the Discussion describes it as fully virulent. (LLM, conf=0.94)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition to the classical ETC, many pathogenic fungi possess a cyanide-insensitive alternative pathway, not found in mammals, which permits respiration when the classical chain is inhibited (Huh and Kang 1999).”
§ The potential of respiration inhibition as a new approach to combat human fungal pathogens > Targeting alternative oxidase function
What the sources say
- Partly supportedcites Huh and Kang 1999 sourceExperimental — accuracy not yet measured
The Abstract says fungi possess a cyanide-resistant alternative respiratory pathway, and the section on C. albicans and S. cerevisiae strains reports that C. albicans maintained cyanide-resistant respiration when the cytochrome pathway was inhibited by antimycin A. The copy does not establish that many pathogenic fungi possess the pathway or state that it is absent from mammals. Page numbers were not provided for these passages. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Fungal-specific inhibitors of Complex III were identified in a screen to identify compounds which reverse azole resistance (Vincent et al. 2016).”
§ The potential of respiration inhibition as a new approach to combat human fungal pathogens > Respiration inhibition can be synergistic with current antifungals
What the sources say
- Supportedcites Vincent et al. 2016 source
The Results section on identifying compounds that reverse fluconazole resistance describes the screen and selection of the indazole series. Subsequent Results sections identify cytochrome bc1 as Complex III and show that the screen-derived Inz-1 inhibits the fungal enzyme more strongly than the human enzyme. Page numbers are not available in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inhibition of Complex III and the alternative oxidase in combination enhances susceptibility to caspofungin in C. parapsilosis (Chamilos et al. 2006).”
§ The potential of respiration inhibition as a new approach to combat human fungal pathogens > Respiration inhibition can be synergistic with current antifungals
What the sources say
- Supportedcites Chamilos et al. 2006 source
The paper reports that simultaneous inhibition of respiratory pathways in three C. parapsilosis clinical isolates lowered caspofungin MICs; its XTT and disk-diffusion experiments used antimycin A and BHAM together. The respiratory-network description identifies complex III in the classical pathway and alternative oxidase in an alternative pathway. BHAM also inhibits the parallel respiratory chain, so the experiment did not isolate the effects of complex III and alternative oxidase alone. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
31 more claims · 12 with their cited sources checked
Create a free account to see all 61 claims and to verify the 4 references still open.
- It may state two separate claims as one. 23
- Probably not a substantial claim. 6
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the interplay between cell wall integrity and mitochondrial homeostasis remains poorly characterized, accumulating evidence indicates that mitochondrial dysfunction in fungal cells correlates with compromised cell wall architecture [13].”
From Mitochondrial anchor protein Num11 is key to pathogenicity of Candida albicans by affecting mitochondrial function and cell wall masking (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Found in diverse microbial pathogens, but not in humans, Aox is proposed as a potential drug target given its reported role in governing diverse cellular stress response pathways, including a role in maintaining cell wall architecture16,17.”
From Multifactor transcriptional control of alternative oxidase induction integrates diverse environmental inputs to enable fungal virulence (2023) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In pathogenic fungi including C. albicans, Cryptococcus neoformans, and Aspergillus fumigatus, inhibiting the respiratory chain can affect the morphological transition from yeast to hyphae, cell wall biogenesis, drug resistance, and virulence [10–17].”
From Mitochondrial anchor protein Num11 is key to pathogenicity of Candida albicans by affecting mitochondrial function and cell wall masking (2025) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Found in diverse microbial pathogens, but not in humans, Aox is proposed as a potential drug target given its reported role in governing diverse cellular stress response pathways, including a role in maintaining cell wall architecture16,17.”
From Multifactor transcriptional control of alternative oxidase induction integrates diverse environmental inputs to enable fungal virulence (2023) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“In C. albicans and other fungi, the importance of the classical ETC for virulence is well established16,20,21.”
From Multifactor transcriptional control of alternative oxidase induction integrates diverse environmental inputs to enable fungal virulence (2023) · cites this paper as [16]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The potential of respiration inhibition as a new approach to combat human fungal pathogens > Respiration inhibition can be synergistic with current antifungals
“Respiration-deficient mutants show a defect in ergosterol biosynthesis, and thus are sensitive to polyenes such as Amphotericin B (Geraghty and Kavanagh 2003a).”
§ The potential of respiration inhibition as a new approach to combat human fungal pathogens > References
“Disruption of mitochondrial function in Candida albicans leads to reduced cellular ergosterol levels and elevated growth in the presence of amphotericin B”
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Martínez, J. L. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00001 · Cited by 2,101
Blumberg, H. M., Jarvis, W. R., Soucie, J. M., Edwards, J. E., Patterson, J. E., Pfaller, M. A., Rangel‐Frausto, M. S., Rinaldi, M. G., Saiman, L., Wiblin, R. T., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/321811 · Cited by 661
Sierotzki, H., & Scalliet, G. (2013) · Phytopathology® · doi:10.1094/phyto-01-13-0009-rvw · Cited by 564
Nitric oxide inhibition of mitochondrial respiration and its role in cell death
Brown, G. C., & Borutaite, V. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)01112-7 · Cited by 377
Mechanisms of resistance to QoI fungicides in phytopathogenic fungi.
Fernández‐Ortuño, D., Torés, J. A., de Vicente, A., & Pérez‐García, A. (2008) · PubMed · Cited by 236
Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi
McCarthy, M. W., Kontoyiannis, D. P., Cornely, O. A., Perfect, J. R., & Walsh, T. J. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix130 · Cited by 169
Marr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A., & White, T. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2584 · Cited by 166
Gussow, A. B., Copeland, B. R., Dhindsa, R. S., Wang, Q., Petrovski, S., Majoros, W. H., Allen, A. S., & Goldstein, D. B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0181604 · Cited by 164
Candida auris : An emerging multidrug-resistant pathogen
Sears, D., & Schwartz, B. S. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.08.017 · Cited by 146
Cited by
Costa-de-Oliveira, S., & Rodrigues, A. G. (2020) · Microorganisms · doi:10.3390/microorganisms8020154 · Cited by 229
Pellón, A., Nasab, S. D. S., & Moyes, D. L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00081 · Cited by 110
“albicans relies on OxPhos to produce ATP and therefore, mitochondria can be targeted for new antifungal drugs (Duvenage et al., 2019a).”
BackgroundJin, X., Zhang, M., Lu, J., Duan, X., Chen, J., Liu, Y., Chang, W., & Lou, H. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.06.016 · Cited by 75
“Moreover, the transcription of alternative oxidase encoding genes AOX1 and AOX2was upregulated by hinokitiol treatment, possibly as feedback from inhibition of the classical respiratory chain, as AOX-based respiration allows respiration when the classical chain is suppressed [32].”
BackgroundTargeting the ATP synthase in bacterial and fungal pathogens: beyond Mycobacterium tuberculosis
Vestergaard, M. R., Bald, D., & Ingmer, H. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.01.026 · Cited by 65
Succinate Dehydrogenase and Ribonucleic Acid Networks in Cancer and Other Diseases
Moreno, C., Santos, R. M., Burns, R., & Zhang, W. C. (2020) · Cancers · doi:10.3390/cancers12113237 · Cited by 62
“Most of the fungicides are designed to combat human fungal pathogens through inhibiting cellular mitochondrial respiration such as SDH activities in fungi [146].”
Background
Metadata
- Authors
- Duvenage, L., Munro, C. A., & Gourlay, C. W.
- Affiliations
- University of Kent (GB)
- University of Aberdeen (GB)
- Corresponding author
- Gourlay, Campbell W.
- Venue
- Current Genetics
- Published
- 2019-06-06
- Volume
- 65
- Issue
- 6
- Pages
- 1347-1353
- ISSN
- 0172-8083 (ISSN-L)
- 1432-0983
- PMC
- PMC6820612
- OpenAlex
- W2950242080
- Cited by
- 52
- References
- 59
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 7 · 2023: 7 · 2022: 6 · 2021: 12 · 2020: 5
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Current Genetics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Kent Academic Repository (University of Kent) (submittedVersion, cc-by)
- Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
- Funders
- Wellcome (097377/Z/11/Z)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Keywords
- respiration inhibition, electron transport chain, human fungal pathogens, Candida albicans, mitochondria, therapeutic target, fungicides, drug resistance, virulence, yeast-to-hypha transition, stress adaptation
- MeSH terms
- Antifungal Agents, Candida albicans, Electron Transport Complex IV, Drug Therapy, Combination, Fungi, Humans, Mitochondria, Mycoses, Oxidoreductases, Electron Transport Complex III, Virulence, Electron Transport Complex II, Electron Transport Complex I
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The potential of respiration inhibition as a new approach to combat human fungal pathogens. https://app.cochat.ai/papers/10.1007/s00294-019-01001-w
- The paper
- Duvenage, L., Munro, C. A., & Gourlay, C. W. (2019). The potential of respiration inhibition as a new approach to combat human fungal pathogens. Current Genetics. https://doi.org/10.1007/s00294-019-01001-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.